



UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION IV
612 EAST LAMAR BOULEVARD, SUITE 400
ARLINGTON, TEXAS 76011-4125

December 24, 2009

St. Peter's Community Hospital
ATTN: Rodney Knable, ARRT(N)
Radiation Safety Officer
2475 Broadway
Helena, Montana 59601

SUBJECT: LICENSE AMENDMENT

Please find enclosed Amendment No. 34 to NRC License No. 25-12453-02 naming **Steven E. Liston, M.D., as an authorized user for 10 CFR 35.100 and 35.200 uses. The request to name Dr. Liston as radiation safety officer on this license was not approved due to insufficient training and experience documentation as explained in my facsimile dated November 23, 2009.** An environmental assessment for this action is not required, since this action is categorically excluded under 10 CFR 51.22(c)(14)(iv). You should review the enclosed document carefully and be sure that you understand all conditions. You can contact me at 817-860-8189 if you have any questions about this license.

NRC expects licensees to conduct their programs with meticulous attention to detail and a high standard of compliance. Because of the serious consequences to employees and the public that can result from failure to comply with NRC requirements, you must conduct your radiation safety program according to the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate by NRC regulations 10 CFR Part 19, "Notices, Instructions and Reports to Workers: Inspection and Investigations," 10 CFR Part 20, "Standards for Protection Against Radiation," and other applicable regulations.
2. Notify NRC in writing of any change in mailing address.
3. By 10 CFR 30.36(d) and/or license condition, notify NRC, promptly, in writing, and request termination of the license:
 - a. When you decide to terminate all activities involving materials authorized under the license whether at the entire site or any separate building or outdoor area;
 - b. If you decide not to acquire or possess and use authorized material; or
 - c. When no principal activities under the license have been conducted for a period of 24 months.
4. In accordance with 10 CFR 35.14, notify the NRC no later than 30 days after:
 - a. The date that the licensee permits an individual to work as an authorized user, an authorized nuclear pharmacist or an authorized medical physicist under 10 CFR 35.13(b)(1) through (b)(4);

- b. An authorized user, an authorized nuclear pharmacist, a Radiation Safety Officer, or an authorized medical physicist permanently discontinues duties under the license or has a name change;
 - c. The licensee's mailing address changes;
 - d. The licensee's name changes, but the name change does not constitute a transfer of control of the license as described in 10 CFR 30.34(b); or
 - e. The licensee has added to or changed the areas of use identified in the application or on the license where byproduct material is used in accordance with either 35.100 or 35.200.
5. Request and obtain a license amendment before you:
- a. Change Radiation Safety Officers;
 - b. Order byproduct material in excess of the amount, radionuclide or form authorized on the license;
 - c. Add or change the areas or address(es) of use identified in the license application or on the license, except for areas of use where byproduct material is used only in accordance with either 10 CFR 35.100 or 35.200; or
 - d. Change the name or ownership of your organization.
6. Submit a complete renewal application or termination request at least 30 days before the expiration date on your license. You will receive a reminder notice approximately 90 days before the expiration date. Possession of radioactive material after your license expires is a violation of NRC regulations.

In addition, please note that NRC Form 313 requires the applicant, by signature, to verify that the applicant understands that all statements contained in the application are true and correct to the best of the applicant's knowledge. The signatory for the application should be the licensee or certifying official rather than a consultant. Since the NRC also accepts a letter requesting amendment of an NRC license, the signatory for such a request should also be the licensee or certifying official rather than a consultant.

NRC will periodically inspect your radiation safety program. Failure to conduct your program according to NRC regulations, license conditions, and representations made in your license application and supplemental correspondence with NRC may result in enforcement action against you. This could include issuance of a notice of violation; imposition of a civil penalty; or an order suspending, modifying, or revoking your license as specified in the NRC Enforcement Policy. The NRC Enforcement Policy is available on the following internet address:
<http://www.nrc.gov/reading-rm/doc-collections/enforcement/>.

An electronic version of the NRC's regulations is available on the NRC Web site at www.nrc.gov. Additional information regarding medical uses of radioactive materials may be obtained on the NRC Web site at: <http://www.nrc.gov/materials/miau/med-use-toolkit.html>. This site also provides the updated Training and Experience NRC Form 313A series of forms and guidance, as well as information on the revised regulations for naturally-occurring and accelerator-produced radioactive materials (NARM).

In accordance with 10 CFR 2.390 of the NRC's "Rules of Practice," a copy of this letter and its enclosure will be available electronically for public inspection in the NRC Public Document Room or from the NRC's document system (ADAMS). ADAMS is accessible from the NRC Web site at <http://www.nrc.gov/reading-rm/adams.html>.

Thank you for your cooperation.

Sincerely,

/RA/

Roberto J. Torres, Senior Health Physicist
Nuclear Materials Safety Branch B

Docket: 030-10917
License: 25-12453-02
Controls: 472476

Enclosure: As stated

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. St. Peter's Community Hospital</p> <p>2. 2475 Broadway Helena, Montana 59601</p>	<p>In accordance with letter and facsimile dated November 5, 2009 and November 20, 2009</p> <p>3. License number 25-12453-02 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date August 31, 2013</p> <hr/> <p>5. Docket No. 030-10917 Reference No.</p>
---	--

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Any byproduct material permitted by 10 CFR 35.400</p> <p>E. Gadolinium-153</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed sources (Theragenics Corporation I-125 Model 125.S06 and Pd-103 Model 200)</p> <p>E. Sealed sources (North American Scientific Model MED 3601 or Isotope Products Laboratories Model A3410)</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. 500 millicuries</p> <p>D. 300 millicuries</p> <p>E. 300 millicuries per source; total possession 1 curie</p>
---	--	--

<p>9. Authorized use:</p> <p>A. Any uptake, dilution, and excretion study permitted by 10 CFR 35.100.</p> <p>B. Any imaging and localization study permitted by 10 CFR 35.200.</p> <p>C. Any use permitted by 10 CFR 35.300.</p> <p>D. Any manual brachytherapy procedure permitted by 10 CFR 35.400 for which the patient can be released under the provisions of 10 CFR 35.75.</p> <p>E. For use in ADAC Laboratories Model Vantage line source housing for SPECT cameras.</p>
--

CONDITIONS

<p>10. Licensed material may be used or stored only at the licensee's facility located at:</p> <p>A. Nuclear Medicine Department, 2475 Broadway, Helena, Montana; and</p> <p>B. Cardiology Clinic, Maria Dean Medical Offices, Suite 203, 2475 Broadway, Helena, Montana.</p>

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
25-12453-02

Docket or Reference Number
030-10917

Amendment No. 34

11. The Radiation Safety Officer for this license is Rodney Knable.
12. Licensed material listed in Item 6 above is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user, authorized nuclear pharmacist, and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use:

Authorized Users

Material and Use

James G. Hubbard, M.D.

35.100; 35.200; 35.300 oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries; and gadolinium-153 for use in ADAC Vantage System for transmission diagnostic imaging

Richard Karsh, M.D.

35.100; 35.200; 35.300 (excluding oral administration of sodium iodide I-131 in quantities greater than 30 millicuries); and gadolinium-153 for use in ADAC Vantage System for transmission diagnostic imaging

John McArthur, M.D.

35.100; 35.200; 35.300; and gadolinium-153 for use in ADAC Vantage System for transmission diagnostic imaging

Robert Pfeffer, M.D.

35.300; 35.400

Steven E. Liston, M.D.

35.100; 35.200


13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee is authorized to transport licensed material only in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
25-12453-02Docket or Reference Number
030-10917

Amendment No. 34

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated March 18, 2003 (ML030930294)
- B. Letter dated December 14, 2004 (ML050030179)
- C. Letter dated May 20, 2008 (ML081790492)
- D. Letter dated December 22, 2008 (ML090550024)
- E. Letter dated February 18, 2009 (ML090550024)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

/RA/

Date: December 24, 2009

By:

Roberto J. Torres, Senior Health Physicist
Nuclear Materials Safety Branch B
Region IV
Arlington, Texas 76011